financetom
Business
financetom
/
Business
/
M&A activity to accelerate this year despite war disruption, Goldman Sachs says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
M&A activity to accelerate this year despite war disruption, Goldman Sachs says
Mar 20, 2026 4:27 AM

March 20 (Reuters) - Goldman Sachs ( GS ) expects

mergers and acquisitions activity to be on the upswing this year

despite the disruption caused by the U.S.-Israeli war on Iran,

CEO David Solomon said on Friday.

"While it is difficult to predict the broader economic

effects of the military action by the U.S. and Israel against

Iran, we still see the potential for a more constructive

operating environment," Solomon said in the annual shareholder

letter.

The Wall Street giant said it expects monetary easing,

fiscal stimulus in developed economies, capital investment in

artificial intelligence technologies and a more balanced

regulatory regime in the U.S. to drive M&A activity this year.

Top dealmakers have said that faster deal closings under the

Trump administration haveassuaged worries that many investors

and boardrooms had when there was greater scrutiny under the

Biden administration.

Solomon said CEOs and boards are taking a much more

front-footed approach as they feel more confident in executing

strategic transactions.

"We expect this upswing to continue though a protracted war

or another exogenous event could, of course, change the current

sentiment," Solomon said.

'U.S.-CHINA RESET NEEDED'

Solomon also called for a long-term reset in the U.S.-China

relationship. The world's two biggest economies have been

working towards easing tensions after a period of heated

rhetoric.

U.S. President Donald Trump earlier this week delayed his

highly anticipated trip to Beijing to meet with Chinese

President Xi Jinping as the ‌war with Iran drags on.

"Given how entwined they are, it is important that the U.S.

and China reach a new modus vivendi, not just for the next 12

months, but rather for the next 10 to 20 years," Solomon said.

"We believe there is a roadmap for more meaningful dialogue.

That said, it remains to be seen whether that dialogue will lead

to a significant agreement."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Southern Missouri Bancorp Insider Sold Shares Worth $422,608, According to a Recent SEC Filing
Southern Missouri Bancorp Insider Sold Shares Worth $422,608, According to a Recent SEC Filing
Mar 15, 2024
01:08 PM EDT, 03/15/2024 (MT Newswires) -- Sammy A Schalk, Director, on March 13, 2024, sold 10,000 shares in Southern Missouri Bancorp ( SMBC ) for $422,608. Following the Form 4 filing with the SEC, Schalk has control over a total of 84,355 shares of the company, with 84,355 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/916907/000141588924008081/xslF345X03/form4-03152024_050336.xml Price: 42.28, Change: +0.56, Percent...
US drillers add oil and gas rigs for third time in four weeks - Baker Hughes
US drillers add oil and gas rigs for third time in four weeks - Baker Hughes
Mar 15, 2024
March 15 (Reuters) - U.S. energy firms this week added oil and natural gas rigs for the third time in four weeks, energy services firm Baker Hughes ( BKR ) said in its closely followed report on Friday. The oil and gas rig count, an early indicator of future output, rose by seven to 629 in the week to March...
Update: Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug
Update: Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug
Mar 15, 2024
01:05 PM EDT, 03/15/2024 (MT Newswires) -- (Updates with the company's latest stock move in the headline and first paragraph.) Keros Therapeutics ( KROS ) shares were 4.1% higher in recent Friday trading, a day after the drugmaker said the US Food and Drug Administration gave fast track designation for KER-050 to treat anemia in adults with lower-risk myelodysplastic syndromes....
Curtiss Wright Insider Sold Shares Worth $600,000, According to a Recent SEC Filing
Curtiss Wright Insider Sold Shares Worth $600,000, According to a Recent SEC Filing
Mar 15, 2024
01:07 PM EDT, 03/15/2024 (MT Newswires) -- Paul J Ferdenzi, Vice President and Corporate Secretary, on March 13, 2024, sold 2,500 shares in Curtiss Wright ( CW ) for $600,000. Following the Form 4 filing with the SEC, Ferdenzi has control over a total of 17,383 shares of the company, with 17,383 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/26324/000162828024011377/xslF345X03/wk-form4_1710521716.xml Price: 242.74,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved